AI Drug Discovery Reaches Clinical Stage: Isomorphic Labs' AlphaFold-Powered Pipeline

Isomorphic Labs (Alphabet's drug discovery spinout) has advanced 3 AI-designed compounds to Phase 1 clinical trials, marking a major milestone for AI-native pharmaceutical development. The compounds — targeting a kinase implicated in cancer and two GPCR targets — were designed using AlphaFold 3's protein-ligand binding predictions. Traditional drug discovery timelines: 4-6 years from target to IND. Isomorphic's timeline: 18-24 months. If clinical success rates hold, AI drug discovery could reduce industry R&D costs by 40%.